Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea

J. Y. Kim, E. J. Kim, J. Y. Choi, O. K. Kwon, G. J. Kim, Sang-Yun Choi, S. S. Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The survival time of HIV/AIDS patients in Korea has increased since HAART (highly active anti-retroviral therapy) was introduced. However, the occurrence of drug-resistant strains requires new anti-retroviral drugs, one of which, an integrase inhibitor (INI), was approved by the US Food and Drug Administration (FDA) in 2007. INIs have been used for therapy in many countries and are about to be employed in Korea. Therefore, it is important to identify basic mutant variants prior to the introduction of INIs in order to estimate their efficacy. To monitor potential drug-resistant INI mutations in Korean HIV/AIDS patients, the polymorphism of the int gene was investigated together with the pol gene using a genotypic assay for 75 randomly selected Korean HIV-1 patients newly diagnosed in 2007. The drug-resistant mutation sequences were analysed using the Stanford HIV DB and the International AIDS Society resistance testing-USA panel (IAS-USA). Seventy strains of Korean subtype B were compared with foreign subtype-B strains, and there were no significantly different variants of the int gene region in the study population. Major mutation sites in the integrase (E92Q, F121Y, G140A/S, Y143C/R, Q148H/R/K and N155H) were not detected, and only a few minor mutation sites (L74M, V151I, E157Q, V165I, I203M, S230N and D232N) were identified in 21 strains (28%). Resistance due to mutations in the pol gene was observed in a single strain (1.3%) resistant to protease inhibitors (PIs) and in four strains (5.3%) resistant to reverse transcriptase inhibitors (RTIs). In summary, this demonstrates that INIs will be susceptible to drug naïve HIV/AIDS patients in Korea.

Original languageEnglish
Pages (from-to)1155-1159
Number of pages5
JournalClinical Microbiology and Infection
Volume17
Issue number8
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

Korea
Acquired Immunodeficiency Syndrome
HIV
Mutation
Integrase Inhibitors
pol Genes
Pharmaceutical Preparations
Integrases
Reverse Transcriptase Inhibitors
United States Food and Drug Administration
Protease Inhibitors
Genes
HIV-1
p31 integrase protein, Human immunodeficiency virus 1
Survival
Therapeutics
Population

Keywords

  • Genetic variation
  • HIV-1
  • Integrase inhibitor
  • Polymorphism
  • Resistant mutation

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea. / Kim, J. Y.; Kim, E. J.; Choi, J. Y.; Kwon, O. K.; Kim, G. J.; Choi, Sang-Yun; Kim, S. S.

In: Clinical Microbiology and Infection, Vol. 17, No. 8, 01.08.2011, p. 1155-1159.

Research output: Contribution to journalArticle

Kim, J. Y. ; Kim, E. J. ; Choi, J. Y. ; Kwon, O. K. ; Kim, G. J. ; Choi, Sang-Yun ; Kim, S. S. / Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea. In: Clinical Microbiology and Infection. 2011 ; Vol. 17, No. 8. pp. 1155-1159.
@article{0dcb7064eb6c4ccab5ac09365d0c13ab,
title = "Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-na{\"i}ve patients with HIV/AIDS in Korea",
abstract = "The survival time of HIV/AIDS patients in Korea has increased since HAART (highly active anti-retroviral therapy) was introduced. However, the occurrence of drug-resistant strains requires new anti-retroviral drugs, one of which, an integrase inhibitor (INI), was approved by the US Food and Drug Administration (FDA) in 2007. INIs have been used for therapy in many countries and are about to be employed in Korea. Therefore, it is important to identify basic mutant variants prior to the introduction of INIs in order to estimate their efficacy. To monitor potential drug-resistant INI mutations in Korean HIV/AIDS patients, the polymorphism of the int gene was investigated together with the pol gene using a genotypic assay for 75 randomly selected Korean HIV-1 patients newly diagnosed in 2007. The drug-resistant mutation sequences were analysed using the Stanford HIV DB and the International AIDS Society resistance testing-USA panel (IAS-USA). Seventy strains of Korean subtype B were compared with foreign subtype-B strains, and there were no significantly different variants of the int gene region in the study population. Major mutation sites in the integrase (E92Q, F121Y, G140A/S, Y143C/R, Q148H/R/K and N155H) were not detected, and only a few minor mutation sites (L74M, V151I, E157Q, V165I, I203M, S230N and D232N) were identified in 21 strains (28{\%}). Resistance due to mutations in the pol gene was observed in a single strain (1.3{\%}) resistant to protease inhibitors (PIs) and in four strains (5.3{\%}) resistant to reverse transcriptase inhibitors (RTIs). In summary, this demonstrates that INIs will be susceptible to drug na{\"i}ve HIV/AIDS patients in Korea.",
keywords = "Genetic variation, HIV-1, Integrase inhibitor, Polymorphism, Resistant mutation",
author = "Kim, {J. Y.} and Kim, {E. J.} and Choi, {J. Y.} and Kwon, {O. K.} and Kim, {G. J.} and Sang-Yun Choi and Kim, {S. S.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1111/j.1469-0691.2010.03392.x",
language = "English",
volume = "17",
pages = "1155--1159",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naïve patients with HIV/AIDS in Korea

AU - Kim, J. Y.

AU - Kim, E. J.

AU - Choi, J. Y.

AU - Kwon, O. K.

AU - Kim, G. J.

AU - Choi, Sang-Yun

AU - Kim, S. S.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - The survival time of HIV/AIDS patients in Korea has increased since HAART (highly active anti-retroviral therapy) was introduced. However, the occurrence of drug-resistant strains requires new anti-retroviral drugs, one of which, an integrase inhibitor (INI), was approved by the US Food and Drug Administration (FDA) in 2007. INIs have been used for therapy in many countries and are about to be employed in Korea. Therefore, it is important to identify basic mutant variants prior to the introduction of INIs in order to estimate their efficacy. To monitor potential drug-resistant INI mutations in Korean HIV/AIDS patients, the polymorphism of the int gene was investigated together with the pol gene using a genotypic assay for 75 randomly selected Korean HIV-1 patients newly diagnosed in 2007. The drug-resistant mutation sequences were analysed using the Stanford HIV DB and the International AIDS Society resistance testing-USA panel (IAS-USA). Seventy strains of Korean subtype B were compared with foreign subtype-B strains, and there were no significantly different variants of the int gene region in the study population. Major mutation sites in the integrase (E92Q, F121Y, G140A/S, Y143C/R, Q148H/R/K and N155H) were not detected, and only a few minor mutation sites (L74M, V151I, E157Q, V165I, I203M, S230N and D232N) were identified in 21 strains (28%). Resistance due to mutations in the pol gene was observed in a single strain (1.3%) resistant to protease inhibitors (PIs) and in four strains (5.3%) resistant to reverse transcriptase inhibitors (RTIs). In summary, this demonstrates that INIs will be susceptible to drug naïve HIV/AIDS patients in Korea.

AB - The survival time of HIV/AIDS patients in Korea has increased since HAART (highly active anti-retroviral therapy) was introduced. However, the occurrence of drug-resistant strains requires new anti-retroviral drugs, one of which, an integrase inhibitor (INI), was approved by the US Food and Drug Administration (FDA) in 2007. INIs have been used for therapy in many countries and are about to be employed in Korea. Therefore, it is important to identify basic mutant variants prior to the introduction of INIs in order to estimate their efficacy. To monitor potential drug-resistant INI mutations in Korean HIV/AIDS patients, the polymorphism of the int gene was investigated together with the pol gene using a genotypic assay for 75 randomly selected Korean HIV-1 patients newly diagnosed in 2007. The drug-resistant mutation sequences were analysed using the Stanford HIV DB and the International AIDS Society resistance testing-USA panel (IAS-USA). Seventy strains of Korean subtype B were compared with foreign subtype-B strains, and there were no significantly different variants of the int gene region in the study population. Major mutation sites in the integrase (E92Q, F121Y, G140A/S, Y143C/R, Q148H/R/K and N155H) were not detected, and only a few minor mutation sites (L74M, V151I, E157Q, V165I, I203M, S230N and D232N) were identified in 21 strains (28%). Resistance due to mutations in the pol gene was observed in a single strain (1.3%) resistant to protease inhibitors (PIs) and in four strains (5.3%) resistant to reverse transcriptase inhibitors (RTIs). In summary, this demonstrates that INIs will be susceptible to drug naïve HIV/AIDS patients in Korea.

KW - Genetic variation

KW - HIV-1

KW - Integrase inhibitor

KW - Polymorphism

KW - Resistant mutation

UR - http://www.scopus.com/inward/record.url?scp=79960662891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960662891&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2010.03392.x

DO - 10.1111/j.1469-0691.2010.03392.x

M3 - Article

VL - 17

SP - 1155

EP - 1159

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 8

ER -